Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States.


Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
03 2022
Historique:
pubmed: 26 10 2021
medline: 15 4 2022
entrez: 25 10 2021
Statut: ppublish

Résumé

This analysis examined trends in incidence and survival among US adults with myeloproliferative neoplasms, including essential thrombocythemia (ET;

Identifiants

pubmed: 34689695
doi: 10.1080/10428194.2021.1992756
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

694-702

Auteurs

Srdan Verstovsek (S)

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jingbo Yu (J)

Incyte Corporation, Wilmington, DE, USA.

Robyn M Scherber (RM)

Incyte Corporation, Wilmington, DE, USA.

Sumit Verma (S)

STATinMED Research, Plano, TX, USA.

Christopher Dieyi (C)

STATinMED Research, Plano, TX, USA.

Chien-Cheng Chen (CC)

STATinMED Research, Plano, TX, USA.

Shreekant Parasuraman (S)

Incyte Corporation, Wilmington, DE, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH